Uppala Praveen Kumar, Varghese Anjaly Mary, Yella Sree Sudha Tanguturi, Velmurugan Hemasri, Thangaraju Pugazhenthan, Krishna Sasanka Kota Shesha Brahma Shree
Santhiram Medical College, Nandyal, Andhra Pradesh, India.
Department of Pharmacology, Santhiram Medical College, Nandyal, Andhra Pradesh, India.
Infect Disord Drug Targets. 2023;23(1):e140622205973. doi: 10.2174/1871526522666220614162117.
Capecitabine, a prodrug of 5-fluorouracil, is an FDA-approved drug for adjuvant treatment of colon, metastatic colorectal, and breast cancer. A variety of mucocutaneous adverse effects has been recognized with capecitabine. The pathogenesis of such manifestations still remains an enigma though various theories have been proposed. Here, we report two such cases. A 59-year-old female with carcinoma of the sigmoid colon on palliative therapy developed localized cutaneous hyperpigmentation of the palms and soles secondary to capecitabine in her 2nd cycle. Another case was of a 42-year-old female with stomach adenocarcinoma, who developed similar adverse effects after administration of capecitabine in her 4th cycle. Since these drugs have been widely used in recent years due to their relative ease in administration, the relative unawareness of Hand-foot syndrome (HFS) caused due to this drug makes it a prudent topic to be reported.
卡培他滨是5-氟尿嘧啶的前体药物，是一种经美国食品药品监督管理局（FDA）批准用于结肠癌、转移性结直肠癌和乳腺癌辅助治疗的药物。卡培他滨已被确认会引发多种皮肤黏膜不良反应。尽管已经提出了各种理论，但这些表现的发病机制仍然是个谜。在此，我们报告两例这样的病例。一名59岁的乙状结肠癌女性在接受姑息治疗时，在第2个疗程因卡培他滨出现了手掌和脚底局部皮肤色素沉着。另一例是一名42岁的胃腺癌女性，在第4个疗程服用卡培他滨后出现了类似的不良反应。由于这些药物近年来因其给药相对简便而被广泛使用，因此对这种药物引起的手足综合征（HFS）相对缺乏认识，这使得它成为一个值得报告的审慎话题。
